Cargando…
Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: Individualized administration based on physiological development and CYP2D6 genotypes
Objective: This study aims to develop a combined population pharmacokinetic (PPK) model for aripiprazole (ARI) and its main active metabolite dehydroaripiprazole (DARI) in pediatric patients with tic disorders (TD), to investigate the inter-individual variability caused by physiological and genetic...
Autores principales: | Xin, Yingying, Gao, Liuliu, Tuo, Yali, Nie, Gang, Mei, Yan, Chen, Chen, Wang, Jun, Li, Sichan, Sun, Dan, Qian, Qiaoqiao, Fu, Yongli, Wang, Yang, Liu, Zhisheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755210/ https://www.ncbi.nlm.nih.gov/pubmed/36532742 http://dx.doi.org/10.3389/fphar.2022.1048498 |
Ejemplares similares
-
Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children
por: Wang, Yang, et al.
Publicado: (2022) -
Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
por: Kneller, Lisa Alina, et al.
Publicado: (2021) -
Aripiprazole-associated tic in a schizophrenia patient
por: Guo, Xieli, et al.
Publicado: (2015) -
Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021) -
Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)